CO5640038A2 - Macrociclos derivados de la quinazolina como agentes antiproliferativos - Google Patents

Macrociclos derivados de la quinazolina como agentes antiproliferativos

Info

Publication number
CO5640038A2
CO5640038A2 CO05119403A CO05119403A CO5640038A2 CO 5640038 A2 CO5640038 A2 CO 5640038A2 CO 05119403 A CO05119403 A CO 05119403A CO 05119403 A CO05119403 A CO 05119403A CO 5640038 A2 CO5640038 A2 CO 5640038A2
Authority
CO
Colombia
Prior art keywords
alkyl
amino
halo
mono
optionally substituted
Prior art date
Application number
CO05119403A
Other languages
English (en)
Inventor
Edgard Freyne Eddy Jean
Timothy Pietyro Suren Perera
Peter Jacobus Johannes Antonius Buijnsters
Marc Willems
Gaston Stanislas Marcell Diels
Werner Constant Johan Embrechts
Holte Peter Ten
Frederick Jan Rita Rombouts
Fademrecht Carsten Schultz
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33493782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5640038(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CO5640038A2 publication Critical patent/CO5640038A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/93Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms

Abstract

1.- Un compuesto que posee la fórmulalas formas N-óxidos, las sales de adición aceptables para uso farmacéutico y las formas estereoquímicamente isómeras del mismo, donde:Z representa O, CH2, NH o S; en particular Z representa NH;Y representa -alquilo C3-C9-, -alquenilo C3-C9-, -alquinilo C3-C9-, -alquilo C3-C7-CO-NH- sustituido en forma optativa con amino, mono- o di(alquil C1-4)amino o alquiloxicarbonilamino C1-4-, -alquenil-C3-7-CO-NH- opcionalmente sustituido con amino, mono- o di(alquil C1-4)amino o alquiloxicarbonilamino C1-4-, -alquinil-C3-7-CO-NH- opcionalmente sustituido con amino, mono- o di(alquil C1-4)amino o alquiloxicarbonilamino C1-4-, -alquiloxi-C1-5- alquilo C1-5-, -alquil-C1-5-NR13-alquilo C1-5, -alquil-C1-5-NR14-CO-alquilo C1-5, -alquil-C1-5-CO-NR15-alquilo C1-5-, -alquil-C1-6-CO-NH-, -alquil-C1-6-NH-CO-, -aIquil-C1-3-NH-CS-Het20-, -alquil-C1-3-NH-CO-Het20-, -alquil-C1-2-CO-Het21-CO-, -Het22-CH2-CO-NH-alquilo C1-3-, -CO-NH-alquilo C1-6-, -NH-CO-alquilo C1-6-, -CO-alquilo C1-7, -alquil-C1-7-CO-, -alquil-C1-6-CO-alquilo C1-6-, -alquil-C1-2-NH-CO-CR16R17-NH-, -alquil-C1-2-CO-NH-CR18R19-CO-, -alquil-C1-2-CO-NR20-alquil-C1-3-CO-, -alquil-C1-2-NR21-CH2-CO-NH-alquilo C1-3- o -NR22-CO-alquil-C1-3-NH-;X1 representa una unión directa, O, -O-alquil-C1-2-, CO, -CO-alquilo C1-2-, NR11, -NR11-alquilo C1-2-, -CH2-, -O-N=CH- o -alquilo C1-2-;X2 representa una unión directa, O, -O-alquilo C1-2-, CO, -CO-alquilo C1-2-, NR12, -NR12-alquilo C1-2-, -CH2-, -O-N=CH- o -alquilo C1-2-;R1 representa hidrógeno, ciano, halo, hidroxi, formilo, alcoxi C1-6-, alquilo C1-6-, halo-fenil-carbonilamino-, alcoxi C1-6- sustituido con halo, ...
CO05119403A 2003-05-27 2005-11-24 Macrociclos derivados de la quinazolina como agentes antiproliferativos CO5640038A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP0305723 2003-05-27
EP0310266 2003-09-15
EP0351061 2003-12-18

Publications (1)

Publication Number Publication Date
CO5640038A2 true CO5640038A2 (es) 2006-05-31

Family

ID=33493782

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05119403A CO5640038A2 (es) 2003-05-27 2005-11-24 Macrociclos derivados de la quinazolina como agentes antiproliferativos

Country Status (32)

Country Link
US (4) US7648975B2 (es)
EP (2) EP2305687A1 (es)
JP (1) JP4887151B2 (es)
KR (1) KR101143878B1 (es)
CN (1) CN102718775B (es)
AR (2) AR045687A1 (es)
AT (1) ATE544454T1 (es)
AU (1) AU2004243487B2 (es)
BR (1) BRPI0410714B8 (es)
CA (1) CA2525214C (es)
CL (1) CL2004001267A1 (es)
CO (1) CO5640038A2 (es)
CY (1) CY1113002T1 (es)
DK (1) DK1633365T3 (es)
EA (1) EA009064B1 (es)
ES (1) ES2381976T3 (es)
HK (1) HK1176350A1 (es)
HR (1) HRP20120351T1 (es)
IL (3) IL172154A0 (es)
IS (1) IS3030B (es)
JO (1) JO2785B1 (es)
MX (1) MXPA05012762A (es)
MY (1) MY148633A (es)
NO (1) NO334209B1 (es)
NZ (1) NZ544154A (es)
PA (1) PA8603801A1 (es)
PL (1) PL1633365T3 (es)
PT (1) PT1633365E (es)
SI (1) SI1633365T1 (es)
TW (3) TWI379835B (es)
UA (1) UA84010C2 (es)
WO (1) WO2004105765A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2785B1 (en) 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
US7750160B2 (en) * 2003-11-13 2010-07-06 Ambit Biosciences Corporation Isoxazolyl urea derivatives as kinase modulators
EA013904B1 (ru) 2003-12-18 2010-08-30 Янссен Фармацевтика Н.В. Пиридо- и пиримидопиримидиновые производные в качестве антипролиферативных агентов
AU2004298784B2 (en) 2003-12-18 2011-06-09 Janssen Pharmaceutica N.V 3-cyano-quinoline derivatives with antiproliferative activity
MY169441A (en) 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
EP1854789B1 (en) 2005-02-23 2013-10-09 Shionogi & Co., Ltd. Quinazoline derivative having tyrosine kinase inhibitory activity
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
JP5345388B2 (ja) * 2005-06-30 2013-11-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 環式アニリノ−ピリジノトリアジン
EP2044084B1 (en) * 2006-07-13 2016-02-17 Janssen Pharmaceutica NV Mtki quinazoline derivatives
JP2009242240A (ja) * 2006-08-04 2009-10-22 Mebiopharm Co Ltd 含ホウ素キナゾリン誘導体
SG174774A1 (en) 2006-09-11 2011-10-28 Curis Inc Quinazoline based egfr inhibitors containing a zinc binding moiety
CA2662587C (en) * 2006-09-11 2013-08-06 Curis, Inc. Quinazoline based egfr inhibitors
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
CA2664145A1 (en) * 2006-10-27 2008-05-02 Janssen Pharmaceutica Nv Use of a mt kinase inhibitor for treating or preventing brain cancer
WO2008049930A2 (en) * 2006-10-27 2008-05-02 Janssen Pharmaceutica Nv A method for profiling kinase inhibitors
BRPI0718021A2 (pt) * 2006-10-27 2013-11-12 Janssen Pharmaceutica Nv Uso de mtki 1 para tratar ou prevenir câncer ósseo
EA200970419A1 (ru) * 2006-10-27 2009-10-30 Янссен Фармацевтика Нв Микроциклические хиназолиновые производные в качестве ингибиторов vegfr3
WO2008087736A1 (ja) * 2007-01-19 2008-07-24 Ube Industries, Ltd. アラルキルオキシ又はヘテロアラルキルオキシ基を有する芳香族アミンの製法
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
JP5536647B2 (ja) 2007-07-27 2014-07-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ピロロピリミジン
US8119616B2 (en) 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
CL2008003384A1 (es) * 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
PT2350075E (pt) 2008-09-22 2014-06-09 Array Biopharma Inc Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
SG10201914059WA (en) 2008-10-22 2020-03-30 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
WO2010085597A1 (en) * 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
TWI406853B (zh) * 2010-04-07 2013-09-01 Dev Center Biotechnology Egfr與vegfr-2雙重抑制劑及其用途與製法
MX365251B (es) 2010-05-20 2019-05-28 Array Biopharma Inc Compuestos macrocíclicos como inhibidores de trk cinasa.
WO2013126015A1 (en) 2012-02-23 2013-08-29 N. V. Nutricia Composition comprising non- digestible oligosaccharides
ES2621220T3 (es) * 2012-03-06 2017-07-03 Pfizer Inc. Derivados macrocíclicos para el tratamiento de enfermedades proliferativas
CN104513253A (zh) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
KR102256242B1 (ko) * 2014-02-07 2021-05-26 엑시테라 파마슈티컬스 인코퍼레이티드 치료 화합물 및 조성물
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
CN113354649A (zh) 2014-11-16 2021-09-07 阵列生物制药公司 一种新的晶型
EP3359526A4 (en) 2015-10-05 2019-04-03 The Trustees of Columbia University in the City of New York ACTIVATORS OF AUTOPHAGIC FLOW AND PHOSPHOLIPASE D AND CLAIRANCE OF PROTEIN AGGREGATES COMPRISING TAU AND TREATMENT OF PROTEINEOPATHIES
CA3003153A1 (en) 2015-10-26 2017-05-04 Loxo Oncology, Inc. Point mutations in trk inhibitor-resistant cancer and methods relating to the same
US10716869B2 (en) 2016-02-29 2020-07-21 Oncodesign Sa Radiolabeled macrocyclic EGFR inhibitor
PE20181888A1 (es) 2016-04-04 2018-12-11 Loxo Oncology Inc Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
RU2745953C2 (ru) 2016-05-18 2021-04-05 Локсо Онколоджи, Инк. Способ получения (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)-пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида и его солей
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
KR20200096941A (ko) 2017-12-07 2020-08-14 앰플릭스 파마슈티컬스, 인크. 헤테로사이클 치환된 피리딘 유도체 항진균제
JP2021530445A (ja) 2018-06-25 2021-11-11 アンプリックス ファーマシューティカルズ,インク. 複素環およびアミノ基によって置換されたピリジン誘導体
US20230159556A1 (en) * 2020-04-20 2023-05-25 Tenova Pharmaceuticals Inc. Novel protein kinase inhibitors
TW202333709A (zh) 2021-12-16 2023-09-01 美商奇奈特生物製藥公司 Met激酶抑制劑
WO2024017258A1 (zh) * 2022-07-19 2024-01-25 百极弘烨(南通)医药科技有限公司 Egfr小分子抑制剂、含其的药物组合物及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE558251A (es) * 1956-06-11
DE2423536A1 (de) * 1974-05-15 1975-11-27 Bayer Ag 3-amino-phenylessigsaeure-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide
US4066772A (en) * 1975-07-21 1978-01-03 Janssen Pharmaceutica N.V. 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds
NZ181256A (en) * 1975-07-21 1978-04-28 Janssen Pharmaceutica Nv 1-(w-benzazol-11-ylalkyl)-piperidine derivatives and pharmaceutical compositions containing certain of these derivatives
US4126688A (en) 1976-05-17 1978-11-21 Janssen Pharmaceutica N.V. Antiemetic 1-(benzotriazolyl-alkyl)-piperidine derivatives
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
PL190489B1 (pl) * 1996-04-12 2005-12-30 Warner Lambert Co Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
IL142257A0 (en) 1998-10-01 2002-03-10 Astrazeneca Ab Amide derivatives, process for their preparation, compositions containing them and use thereof in the manufacture of a medicament for the treatment of cytokine-mediated diseases
FR2809400B1 (fr) * 2000-05-25 2004-04-09 Inst Francais Du Petrole Materiaux comportant des groupements organiques contenant du soufre et du phosphore lie par l'intermediaire d'atomes d'oxygenes a un oxyde mineral
JO2785B1 (en) * 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
GB2437114B (en) * 2006-04-13 2008-12-17 Siemens Magnet Technology Ltd Method Of Manufacturing A Solenoidal Magnet

Also Published As

Publication number Publication date
AU2004243487A1 (en) 2004-12-09
US20060247237A1 (en) 2006-11-02
AR092137A2 (es) 2015-03-25
CA2525214C (en) 2012-11-27
CL2004001267A1 (es) 2005-04-22
KR101143878B1 (ko) 2012-05-24
US20130178624A1 (en) 2013-07-11
EP1633365A1 (en) 2006-03-15
IS3030B (is) 2021-06-15
PL1633365T3 (pl) 2012-07-31
TW201245111A (en) 2012-11-16
TW201245160A (en) 2012-11-16
JO2785B1 (en) 2014-03-15
IL233046A0 (en) 2014-07-31
HRP20120351T1 (hr) 2012-05-31
NO334209B1 (no) 2014-01-13
TWI468372B (zh) 2015-01-11
IL233045B (en) 2018-07-31
EP1633365B1 (en) 2012-02-08
BRPI0410714A (pt) 2006-06-13
PT1633365E (pt) 2012-05-07
BRPI0410714B8 (pt) 2021-05-25
US20100105668A1 (en) 2010-04-29
DK1633365T3 (da) 2012-05-14
MXPA05012762A (es) 2006-02-13
ES2381976T3 (es) 2012-06-04
NO20056196L (no) 2005-12-28
JP2007504276A (ja) 2007-03-01
US9273013B2 (en) 2016-03-01
EP2305687A1 (en) 2011-04-06
PA8603801A1 (es) 2004-12-16
TWI468397B (zh) 2015-01-11
MY148633A (en) 2013-05-15
BRPI0410714B1 (pt) 2019-09-24
SI1633365T1 (sl) 2012-06-29
CA2525214A1 (en) 2004-12-09
WO2004105765A1 (en) 2004-12-09
EA200501866A1 (ru) 2006-06-30
JP4887151B2 (ja) 2012-02-29
EA009064B1 (ru) 2007-10-26
ATE544454T1 (de) 2012-02-15
TW200510431A (en) 2005-03-16
IL233045A0 (en) 2014-07-31
HK1176350A1 (zh) 2013-07-26
US8394786B2 (en) 2013-03-12
IS8077A (is) 2005-10-14
CN102718775A (zh) 2012-10-10
IL172154A0 (en) 2006-04-10
CN102718775B (zh) 2016-02-17
AU2004243487B2 (en) 2009-12-03
TWI379835B (en) 2012-12-21
KR20060014415A (ko) 2006-02-15
US7648975B2 (en) 2010-01-19
AR045687A1 (es) 2005-11-09
UA84010C2 (en) 2008-09-10
US20160207938A1 (en) 2016-07-21
NZ544154A (en) 2009-01-31
CY1113002T1 (el) 2016-04-13

Similar Documents

Publication Publication Date Title
CO5640038A2 (es) Macrociclos derivados de la quinazolina como agentes antiproliferativos
RS50510B (sr) Formulacije koje sadrže ekteinascidin i disaharid
CR8986A (es) Isoxazoles sustituidos como fungicidas
EA200701790A1 (ru) Твёрдый фармацевтический дозированный состав
SV2005002048A (es) " combinaciones antineoplasticas de cci - 779 y rituximab " ref. am - 101608salvo
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
NO20061722L (no) Nye GLP-1 derivater
SE0301653D0 (sv) Novel compounds
ZA200608416B (en) Herbicidal composition
IN2012DN02609A (es)
ECSP066481A (es) Formulaciones que contienen cobre
DE602005011780D1 (de) Triazinderivate mit carbamatfunktion
ATE500229T1 (de) Uracilderivate mit herbizider wirkung
MX2007006241A (es) 2-alcoxi-3,4,5-trihidroxi-alquilamidas, su preparacion, composiciones que las contienen y su utilizacion.
RS50611B (sr) "BEZILAT SO 7 - (2- (4- (3 – TRIFLUOROMETIL - FENIL) -1, 2, 3, 6" TETRAHIDRO - PIRID-1- ILI)ETIL)IZOHINOLlNA, NJENO DOBIJANJE I NJENA TERAPEUTSKA PRIMENA
ATE509933T1 (de) Pentacyclische kinaseinhibitoren
BRPI0414933A (pt) derivativos de imidazopiridina como inibidores de óxido nìtrico sintase induzìvel
ITBO20020544A1 (it) Uso di farine vegetali come agenti biotossici ad azione ammendante.
ATE404602T1 (de) Wässrige polyurethanzubereitungen
SE0301654D0 (sv) Novel compounds
PA8557201A1 (es) Compuestos basicos lineales que tienen actividad antagonista de nk-2 y su formulaciones
DE602004013011D1 (de) Haarbehandlungszusammensetzungen
ATE294154T1 (de) Apfelsäureadditionssalze von terbinafin
EA200300917A1 (ru) Порошковый состав
WO2005002570A8 (en) Use of an aziridino compound to selectively inactivate parasites in biological compositions

Legal Events

Date Code Title Description
FG Application granted